Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies

Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase... Adv Ther (2017) 34:2625–2637 DOI 10.1007/s12325-017-0642-4 ORIGINAL RESEARCH Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies . . . Tomohiro Kusawake James J. Keirns Donna Kowalski . . . Martin den Adel Dorien Groenendaal-van de Meent Akitsugu Takada Yoshiaki Ohtsu Masataka Katashima Received: September 20, 2017 / Published online: November 13, 2017 The Author(s) 2017. This article is an open access publication Amenamevir was administered orally at various ABSTRACT doses as a single dose (5–2400 mg) or daily (300 or 600 mg/day) for 7 days. Introduction: Amenamevir (ASP2151) is a Results: Following single and multiple oral nonnucleoside antiherpesvirus compound doses, amenamevir demonstrated a less than available for the treatment of varicella–zoster dose proportional increase in the pharmacoki- virus infections. In this article we summarize netic parameters area under the plasma drug the findings of four phase 1 studies in healthy concentration versus time curve from time zero participants. to infinity (AUC ) and C . After single and inf max Methods: Four randomized phase 1 studies multiple oral 300-mg doses of amenamevir, no investigated the safety and pharmacokinetics of apparent differences in pharmacokinetics were single and multiple doses of amenamevir, observed between http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Advances in Therapy Springer Journals

Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies

Loading next page...
 
/lp/springer_journal/pharmacokinetics-and-safety-of-amenamevir-in-healthy-subjects-analysis-ncuymV0ZiB
Publisher
Springer Healthcare
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Oncology; Cardiology; Rheumatology; Endocrinology; Pharmacology/Toxicology
ISSN
0741-238X
eISSN
1865-8652
D.O.I.
10.1007/s12325-017-0642-4
Publisher site
See Article on Publisher Site

Abstract

Adv Ther (2017) 34:2625–2637 DOI 10.1007/s12325-017-0642-4 ORIGINAL RESEARCH Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies . . . Tomohiro Kusawake James J. Keirns Donna Kowalski . . . Martin den Adel Dorien Groenendaal-van de Meent Akitsugu Takada Yoshiaki Ohtsu Masataka Katashima Received: September 20, 2017 / Published online: November 13, 2017 The Author(s) 2017. This article is an open access publication Amenamevir was administered orally at various ABSTRACT doses as a single dose (5–2400 mg) or daily (300 or 600 mg/day) for 7 days. Introduction: Amenamevir (ASP2151) is a Results: Following single and multiple oral nonnucleoside antiherpesvirus compound doses, amenamevir demonstrated a less than available for the treatment of varicella–zoster dose proportional increase in the pharmacoki- virus infections. In this article we summarize netic parameters area under the plasma drug the findings of four phase 1 studies in healthy concentration versus time curve from time zero participants. to infinity (AUC ) and C . After single and inf max Methods: Four randomized phase 1 studies multiple oral 300-mg doses of amenamevir, no investigated the safety and pharmacokinetics of apparent differences in pharmacokinetics were single and multiple doses of amenamevir, observed between

Journal

Advances in TherapySpringer Journals

Published: Nov 13, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off